Last reviewed · How we verify
Ropivacaine Ketorolac
Ropivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while ketorolac provides anti-inflammatory and analgesic effects by inhibiting cyclooxygenase enzymes.
Ropivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while ketorolac provides anti-inflammatory and analgesic effects by inhibiting cyclooxygenase enzymes. Used for Perioperative pain management and anesthesia.
At a glance
| Generic name | Ropivacaine Ketorolac |
|---|---|
| Sponsor | University of Aarhus |
| Drug class | Local anesthetic + NSAID combination |
| Target | Voltage-gated sodium channels (ropivacaine); COX-1/COX-2 (ketorolac) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
This is a combination product where ropivacaine, a long-acting amide local anesthetic, reversibly blocks voltage-gated sodium channels to prevent nerve impulse transmission in localized tissues. Ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), inhibits COX-1 and COX-2 enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Together, they provide both local anesthetic and systemic analgesic/anti-inflammatory effects for perioperative pain management.
Approved indications
- Perioperative pain management and anesthesia
Common side effects
- Injection site reactions
- Nausea
- Dizziness
- Headache
- Gastrointestinal effects (ketorolac component)
Key clinical trials
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- R.E.C.K vs Exparel in Robotic Nephrectomy (PHASE3)
- Postoperative Pain Management Following Robotic Assisted Sacrocolpopexy (NA)
- Single Shot Exparel vs Catheters in Lower Extremity Trauma (PHASE4)
- Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. (PHASE2, PHASE3)
- Pain Management Study (PHASE4)
- Prospective Opioid-Free AIS Fusion (PHASE4)
- Effect of RECK in Posterior Spinal Fusion (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine Ketorolac CI brief — competitive landscape report
- Ropivacaine Ketorolac updates RSS · CI watch RSS
- University of Aarhus portfolio CI